OPAL data is a gem! Large Australian data studying JAKi use in #rheumatoidarthritis N=5900 Switching JAKi~JAKi-common. As in TNFi 1st line Rx had longer retention & better efficacy than 2nd & subsequent. Median 1st advanced Rx - same in all JAKs 34 MOA @RheumNow #ACR22 abst0274 https://t.co/FQU4AKXwe9

Xeljanz in PsA (@pfizer funded) #ACR22 @RheumNow ⚠️safety data -Pancytopenia -Transaminitis -Dyslipidemia -Elevated CPK without #myositis -Avoid in pregnancy and GI strictures 🤰Stop JAKi at least one month prior to conception🤰

Xeljanz use in AS #ACR22 (@pfizer sponsored) @RheumNow -Included patients with at least bilateral grade 2 SI or grade 3/4 unilateral SI -5mg BID Xeljanz -Significantly more patients had ASAS20/40 response, CRP reduction, & QOL, vs. placebo -Onset of action noticed at 2 weeks https://t.co/DisKpgR0pt

@MayoClinic data for bari in relapsing GCA caused waves at #ACR21 Spanish data looking at real-world practice: slightly longer, slower GCA, but equally encouraging outcomes waiting for SELECT-GCA with interest! @EBRheum ABST0464 #ACR22 @RheumNow https://t.co/pVRPXAohhc https://t.co/FgNNfPSWk3

• https://twitter.com/drdavidliew/status/1457688108338606083

OPAL dataset 🇦🇺: 55000+ RA pts, 1/10 first line JAKi. Persistence > if 1st line,< x2 if 3rd line. 1/2 switch JAKi->TNFi 1/3 switch JAKi ->JAKi Why high proportion of JAKi cycling, when AE reason for switch low? https://t.co/APdWW7fzJE Abst #0274 #ACR22 @Rheumnow @ClaireDeakin10 https://t.co/3xM3lQO1wI

• Temporal Trends and Risk of Rheumatoid Arthritis in Celiac Disease Patients: A …

Very helpful slide on the different MOAs of JAK inhibitors (by Lui C et al.) shared by Dr. Langford #ACR22 @RheumNow #RheumTwitter #yearinreview https://t.co/9VIOmzNoMq

Dr. C Langford on #YearinReview: ORAL Surveillance noted NNH=16 in pts w/ASCVD compared to NNH 223 in pts w/o ASCVD. This led to FDA warning on all JAKi; how does not this apply to the new JAKi's? Discussion needed with patients when starting this class of drug #ACR22 @rheumnow https://t.co/XtJVap6yjh

#acr22 The Rise of JAK in rheumatology Look for Ab1117 in plenary 2 tomorrow for DEU and SLE @RheumNow https://t.co/nLpXGyrhfJ

Year in Review #acr22 Oral Surveillance: With ASCVD number needed to harm 16, only 223 without ASCVD Focus on risk stratification ⁦@RheumNow⁩ https://t.co/tJyha1WKfR